Skip to main content
. 2020 Apr 24;12(4):392. doi: 10.3390/pharmaceutics12040392

Figure 5.

Figure 5

(A) Topical and transdermal delivery of ACV from various drug carriers after 48 h, where S/Comix/IPM: 15 wt.% S/Comix at a 2:1 ratio in IPM. W/O: ME9. IL/O: ME1; (B) transdermal permeation profile of ACV from various IL/O MEs with varying S/Co ratios; (C) the total (topical + transdermal) delivery of ACV from various IL/O MEs with varying S/Co ratios after 48 h; (mean ± SD, n = 3, * p < 0.05, *** p < 0.001, and **** p < 0.0001 using Dunnett’s multiple comparison test. All the drug carriers contained 5 mg/mL ACV.